Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer
Authors Monie A, Hung C, Roden R, Wu T
Published 7 March 2008 Volume 2008:2(1) Pages 107—113
Archana Monie1, Chien-Fu Hung1,2, Richard Roden1,2,4, T-C Wu1,2,3,4
1Departments of Pathology, 2Obstetrics and Gynecology, 3Molecular Microbiology and Immunology, and 4Oncology, 5Institute of Genetic Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Abstract: Cervical cancer continues to be the second largest cause of cancer deaths in women worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a necessary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive strategy to prevent cervical cancer. Current strategies for the development of safe and effective preventive vaccines are based on the induction of neutralizing antibodies against the major capsid protein, L1 of HPV. Cervarix™ is one of the preventive HPV vaccines that has been approved in the Europe and Australia and is currently under review by the US Food and Drug Administration. Cervarix is composed of HPV16 and HPV18 L1 virus-like particles (VLPs) formulated in ASO4 adjuvant. Vaccination with Cervarix has been shown to protect women against a high proportion of precursor lesions of cervical cancer caused by these two HPV types. This review explores the various features of this new vaccine candidate and discusses the future directions in the field of HPV vaccine development.
Keywords: HPV, L1, VLP, vaccine, Cervarix
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]